Design, validation and implementation of an automated e-alert for acute kidney injury: 6-month pilot study shows increased awareness.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
27 07 2023
Historique:
received: 03 04 2023
accepted: 07 07 2023
medline: 31 7 2023
pubmed: 28 7 2023
entrez: 27 7 2023
Statut: epublish

Résumé

Acute kidney injury (AKI) is defined as a sudden episode of kidney failure but is known to be under-recognized by healthcare professionals. The Kidney Disease Improving Global Outcome (KDIGO) guidelines have formulated criteria to facilitate AKI diagnosis by comparing changes in plasma creatinine measurements (PCr). To improve AKI awareness, we implemented these criteria as an electronic alert (e-alert), in our electronic health record (EHR) system. For every new PCr measurement measured in the University Medical Center Utrecht that triggered the e-alert, we provided the physician with actionable insights in the form of a memo, to improve or stabilize kidney function. Since e-alerts qualify for software as a medical device (SaMD), we designed, implemented and validated the e-alert according to the European Union In Vitro Diagnostic Regulation (IVDR). We evaluated the impact of the e-alert using pilot data six months before and after implementation. 2,053 e-alerts of 866 patients were triggered in the before implementation, and 1,970 e-alerts of 853 patients were triggered after implementation. We found improvements in AKI awareness as measured by (1) 2 days PCr follow up (56.6-65.8%, p-value: 0.003), and (2) stop of nephrotoxic medication within 7 days of the e-alert (59.2-63.2%, p-value: 0.002). Here, we describe the design and implementation of the e-alert in line with the IVDR, leveraging a multi-disciplinary team consisting of physicians, clinical chemists, data managers and data scientists, and share our firsts results that indicate an improved awareness among treating physicians.

Sections du résumé

BACKGROUND
Acute kidney injury (AKI) is defined as a sudden episode of kidney failure but is known to be under-recognized by healthcare professionals. The Kidney Disease Improving Global Outcome (KDIGO) guidelines have formulated criteria to facilitate AKI diagnosis by comparing changes in plasma creatinine measurements (PCr). To improve AKI awareness, we implemented these criteria as an electronic alert (e-alert), in our electronic health record (EHR) system.
METHODS
For every new PCr measurement measured in the University Medical Center Utrecht that triggered the e-alert, we provided the physician with actionable insights in the form of a memo, to improve or stabilize kidney function. Since e-alerts qualify for software as a medical device (SaMD), we designed, implemented and validated the e-alert according to the European Union In Vitro Diagnostic Regulation (IVDR).
RESULTS
We evaluated the impact of the e-alert using pilot data six months before and after implementation. 2,053 e-alerts of 866 patients were triggered in the before implementation, and 1,970 e-alerts of 853 patients were triggered after implementation. We found improvements in AKI awareness as measured by (1) 2 days PCr follow up (56.6-65.8%, p-value: 0.003), and (2) stop of nephrotoxic medication within 7 days of the e-alert (59.2-63.2%, p-value: 0.002).
CONCLUSION
Here, we describe the design and implementation of the e-alert in line with the IVDR, leveraging a multi-disciplinary team consisting of physicians, clinical chemists, data managers and data scientists, and share our firsts results that indicate an improved awareness among treating physicians.

Identifiants

pubmed: 37501175
doi: 10.1186/s12882-023-03265-4
pii: 10.1186/s12882-023-03265-4
pmc: PMC10375640
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

222

Informations de copyright

© 2023. The Author(s).

Références

Clin Chem Lab Med. 2007;45(1):13-9
pubmed: 17243908
Nat Rev Nephrol. 2021 Jul;17(7):493-502
pubmed: 33712812
J Med Internet Res. 2022 Nov 18;24(11):e40516
pubmed: 36399373
Am J Nephrol. 2012;35(4):349-55
pubmed: 22473149
J Am Soc Nephrol. 2018 Feb;29(2):654-660
pubmed: 29097621
Nephron. 2015;131(2):113-7
pubmed: 26351847
Nephrol Dial Transplant. 2017 Feb 1;32(2):265-272
pubmed: 28088774
BMC Nephrol. 2021 Nov 8;22(1):371
pubmed: 34749693
Clin Chem Lab Med. 2022 May 11;60(7):982-988
pubmed: 35538674
NPJ Digit Med. 2019 Jul 31;2:67
pubmed: 31396561
Dtsch Arztebl Int. 2017 Jan 9;114(1-02):1-8
pubmed: 28143633
Can J Kidney Health Dis. 2016 Feb 26;3:10
pubmed: 26925246
Crit Care Clin. 2020 Jan;36(1):125-140
pubmed: 31733675
Curr Opin Nephrol Hypertens. 2013 Nov;22(6):637-42
pubmed: 24100217
Crit Care Clin. 2021 Apr;37(2):251-266
pubmed: 33752854
Lancet. 2019 Nov 23;394(10212):1949-1964
pubmed: 31777389
Kidney Int. 2020 Aug;98(2):294-309
pubmed: 32709292

Auteurs

Michael S A Niemantsverdriet (MSA)

Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Room number G03.551, UMC Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
, Lichtenauerlaan 40 3062ME, SkylineDx, Rotterdam, The Netherlands.

Wouter M Tiel Groenestege (WM)

Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Room number G03.551, UMC Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.

M Khairoun (M)

Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.

Imo E Hoefer (IE)

Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Room number G03.551, UMC Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.

Wouter W van Solinge (WW)

Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Room number G03.551, UMC Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.

Domenico Bellomo (D)

, Lichtenauerlaan 40 3062ME, SkylineDx, Rotterdam, The Netherlands.

Martin H van Vliet (MH)

, Lichtenauerlaan 40 3062ME, SkylineDx, Rotterdam, The Netherlands.

Karin A H Kaasjager (KAH)

Department of Internal Medicine and Acute Medicine, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.

Saskia Haitjema (S)

Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, Room number G03.551, UMC Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands. s.haitjema@umcutrecht.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH